Treatment of schizophrenia with ergot derivatives

C. A. Tamminga, M. H. Schaffer

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.

Original languageEnglish (US)
Pages (from-to)239-242
Number of pages4
JournalPsychopharmacology
Volume66
Issue number3
DOIs
StatePublished - Dec 1 1979

    Fingerprint

Keywords

  • Bromocriptine
  • CF 25-397
  • Dopamine
  • Ergot derivatives
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this